ViewRay™, Inc., a privately held medical device company, has secured $20 million in Series C financing led by new investor Siemens Venture Capital (SVC) GmbH and joined by existing investors Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors. The funding is intended to move the ViewRay system, a unique image-guided radiation therapy system now in the late stages of development, through the process of commercialization and placement in major medical centers.*

The ViewRay system is designed to improve the accuracy of cancer treatments through a combination of simultaneous magnetic resonance imaging (MRI) and radiotherapy delivery. "MRI-guided radiotherapy has great potential, and we believe ViewRay has the technology and the team to bring it to fruition," said Ralf Schnell, CEO, Siemens Venture Capital.

"We are pleased to welcome SVC to our team, adding to the technology partnership with the Siemens MR business unit of Siemens AG," said Gregory M. Ayers, MD, PhD, ViewRay president and CEO. "The continuing commitment of our present investors is a testament to both the significant progress we have made in development of our system and the overall promise of MRI-guided radiotherapy."

* At this time, the ViewRay system is for nonclinical research use only. The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, will soon become the first in the world to test the ViewRay system.

About ViewRay

ViewRay, Inc., of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. Using MRI-guided radiotherapy, the ViewRay system is intended to provide continuous soft-tissue imaging during treatment. The system is being designed so that clinicians—for the first time—will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. Since 2009, Siemens AG has partnered with ViewRay to develop advanced MRI technology for the ViewRay system. For more information, visit http://www.viewray.com.

About Aisling Capital

Aisling Capital is a dedicated life sciences private equity firm with US$1 billion under management. Headquartered in New York, Aisling Capital invests in both private and public companies, utilizing a wide variety of investment structures. The Aisling Capital team's combination of clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry. For more information, visit http://www.aislingcapital.com.

About Fidelity Biosciences

Fidelity Biosciences is a division of Fidelity Investments, one of the world's leading providers of financial services. For more than 30 years, Fidelity Investments has been a significant presence in the venture capital and private equity industry, investing the firm's own capital since 1969. This provides us with the flexibility and capabilities of traditional venture capital firms while eliminating the additional pressures of fundraising. The result is a clear focus on building long-term value for Fidelity, our management partners, and coinvestors. For more information, visit http://www.fidelitybiosciences.com.

About Kearny Venture Partners

With over $330 million in capital under management, Kearny Venture Partners is a venture capital firm exclusively focused on healthcare products. We believe that the opportunity for entrepreneurs to devise innovative solutions in healthcare has never been greater. Significant unmet needs in healthcare continue to persist, representing large potential market opportunities for safe and effective products. As the molecular basis of disease is increasingly unraveled, new opportunities for intervention emerge. Novel therapies can and will displace incumbent products. For more information, visit http://www.kearnyvp.com.

About OrbiMed Advisors LLC

OrbiMed is the world's largest fully dedicated healthcare investment firm, with over $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds. For more information, visit http://www.orbimed.com.

About Siemens Venture Capital GmbH

Siemens Venture Capital GmbH (SVC), the central venture capital organization within Siemens, invests in early-stage technology companies and established growth companies, focusing on the energy, industry and healthcare sectors. SVC is focused on innovative solutions from which Siemens can profit and plays a key role in Siemens' global innovation network. To date, the company has invested more than EUR 800 million in over 150 companies and 40 venture capital funds. In addition, SVC advises the German Siemens pension funds on their private equity allocation. As part of this relationship, SVC has launched the venture capital fund of funds Siemens Global Innovation Partners I to capitalize on these opportunities.

ViewRay is a trademark of ViewRay, Inc.

SOURCE ViewRay, Inc.

Back to top

RELATED LINKS
http://www.viewray.com

The Illinois Venture Capital Association (IVCA) is pleased to announce its 2010 award recipients.

The Stanley C. Golder Medal will be awarded this year to Lester B. Knight, Founding Partner of RoundTable Healthcare Partners.  The Golder Medal acknowledges individuals who have made profound and lasting contributions to the private equity industry in Illinois.

The Richard J. Daley Medal will be presented to Robert L. Fealy, President of The Duchossois Group and Managing Director of Duchossois Technology Partners.  The Daley Medal recognizes a single individual who has given direct and extraordinary support to the Illinois economy resulting from private equity funding.

The Fellows Medal will be presented to Mark Glennon.  Mark currently serves as Treasurer of IVCA, is a Founding Member of IVCA and has served on numerous IVCA committees.  The Fellows Medal recognizes individuals for their outstanding contributions to the private equity profession and to the Illinois Venture Capital Association.

A new addition to the IVCA Awards this year is the Portfolio Company of the Year Award. This award will go to a VC or PE-backed company with an exit in the last 3 years – through an IPO or a sale – that provided a great return on investment for investors. The inaugural recipient of this award is GTCR-backed Ovation Pharmaceuticals.  Accepting the award on behalf of the Ovation management team will be Jeffrey S. Aronin.  Jeff was a founder of Ovation in 2000, and was President and CEO through the company's sale in 2009.

The dinner to present the awards will be held on Monday, December 6, 2010 at the Four Seasons Hotel Chicago. We have a limited number of sponsorships still available to IVCA members only. To request sponsorship, contact Kathy Pyne at 312.201.2851.

SOURCE Illinois Venture Capital Association

Back to top

RELATED LINKS
http://www.illinoisvc.org

A $100,000 investment fund will be awarded to the top two companies with greatest investment potential as selected by the fund investors: $50,000 Best Technology Investment and $50,000 Best Non-Technology investment, at ZINO Society's 5th annual ZINO Zillionaire Investment Forum September 15, 2010, 8:00 am - 5:00 pm, Bell Harbor Conference Center, Seattle.

Accredited investors, entrepreneurs and business leaders will have the chance to connect throughout the day via 5-minute presentations in front of a Due Diligence LIVE! panel, 2-minute Back-of-the-Napkin presentations with a VC panel, Exhibitions, Table Top Demonstrations in the Beer Garden, and ZINO Zenith Awards and the announcement of Fund Finalists at the Awards and Wine Reception. 

"This new ZZIF format enables 40+ entrepreneurs to be featured and to connect with investors throughout the day," explained Cathi Hatch, ZINO Society Founder and CEO.  

Panelists include: David Allen, Executive VP, McKinstry; Peter Ueberroth, Chairman, Contrarian Group; John Cook, Executive Editor, TechFlash; Bill Bryant, Venture Partner, Draper Fisher Jurvetson; Andy Dale, Managing Director, Montlake Capital; Gregg Bennett, Angel Investor; Troy Hartzell, Managing Partner, Evolution Capital Partners; Ron Howell, CEO, Washington Research Foundation; Daniel Kingston, Managing Partner, Vulcan Capital; Rick LeFaivre, Partner, OVP Venture Partners; Byron McCann, Managing Partner, Ascent; John Otter, President & Managing Partner, Commerce Bridge Company; Gregg Semler, Managing Director, Pivotal Investments; Alan Smith, Partner, Fenwick & West; and Charles Finkelstein, Angel Investor.

About ZINO Society

ZINO Society is a membership network that connects accredited investors with entrepreneurs seeking funding and connects people for business and social interaction, enrichment, education and commerce. Since its inception, ZINO Society has facilitated angel funding in excess of $15 million for early-stage and expansion businesses. More information can be found at zinosociety.com.

SOURCE ZINO Society

Back to top

RELATED LINKS
http://www.zinosociety.com

Ayeah Games has closed a round of seed funding provided by a small group of prominent angel investors and micro-cap venture capital firms. Concurrently, the Boston-based company has introduced "social reality games," which combine social networking, current events and breaking news to deliver a highly interactive entertainment experience.

Ayeah Games is founded by Doug Levin, a serial entrepreneur and founder and current Board of Directors member of Black Duck Software, a Waltham, Mass.-based company that helps its customers evaluate appropriate use of open source software in conjunction with developed and deployed software applications.

"Ayeah Games is about real people and real events and capitalizes on the rapid adoption of Twitter, Facebook and other social media platforms," said Levin. "In many ways, Ayeah is building on the immense popularity of existing online gaming environments, which are easy to use and encourage interaction among friends. By adding in the gossip we all love in our daily lives, Ayeah's experience will be even more viral."

Casual social games are typically browser-based applications with social networking components such as access to one's friends list, "wall" and status updates on Facebook. Unlike most existing games, however, Ayeah Games places users at the intersection of media trends and breaking news, allowing them to interact with others in real-time and see how the day-to-day events impacts their lives.

According to conservative estimates from Screen Digest Reports, the social games market surged to be worth $639 million in 2009, up from $76 million in 2008. The market is forecasted to be worth $1.5 billion in 2014.

Initial investors in Ayeah expressed their resounding support for Ayeah's business model and prospects:

"I'm very excited about the prospects for Ayeah Games," said John Landry, a Boston-area 'Super Angel' and founder of Lead Dog Ventures. "Ayeah's vision and capabilities in developing a new segment in the casual social games space are very impressive."

"Doug Levin is a visionary and a great CEO," said Janpieter Scheerder, general partner of Eureeka Ventures. "With his execution and operational skills he will take Ayeah into the casual social games space and it will emerge a winner."

About Ayeah Games

Ayeah Games, Inc., in Boston, is an interactive entertainment software company. Founded in 2010, the Company develops, publishes, and distributes interactive social reality software for personal computers, wireless devices and the Internet. www.ayeahgames.com - Twitter @ayeahgames.

SOURCE Ayeah Games, Inc.

Back to top

RELATED LINKS
http://www.ayeahgames.com

SOURCE Vokle

Back to top

RELATED LINKS
http://www.vokle.com
http://www.live4Pakistan.tv